Will Medicare Cover Medical Marijuana? Bipartisan Lawmakers Demand Answers in 2026
- OMNI Medical
- 11 minutes ago
- 7 min read
A bipartisan group in Congress wants the Trump administration to explain how federal marijuana rescheduling will affect patients—including whether Medicare could eventually cover medical cannabis. Here is what patients need to know right now.
Could Medicare one day help pay for medical marijuana?
For millions of older Americans and patients living with chronic health conditions, that question is no longer merely theoretical. It is now part of a formal request sent by four members of Congress to President Donald Trump and senior members of his administration.
The lawmakers are asking how the federal government’s evolving Schedule III framework will affect medical marijuana patients, state programs, insurance reimbursement, privacy, home cultivation, healthcare workers and cannabis businesses.
But the most important fact for patients is this:
Congress has asked about Medicare coverage. Medicare has not announced coverage of dispensary medical marijuana.
The letter is a significant sign that federal policymakers are beginning to confront the real-world consequences of rescheduling. It is not, however, a new insurance benefit—and it does not change how Florida patients obtain medical marijuana today.
What Did the Bipartisan Lawmakers Ask?
The August 18, 2026 letter was signed by Representatives Dina Titus of Nevada, David Joyce of Ohio, Ilhan Omar of Minnesota and Greg Steube of Florida. Titus, Joyce and Omar are co-chairs of the Congressional Cannabis Caucus, while Steube has also advocated for moving marijuana to Schedule III.
The lawmakers addressed their questions to President Trump, Attorney General Todd Blanche, Health and Human Services Secretary Robert F. Kennedy Jr. and Treasury Secretary Scott Bessent.
Their questions cover several unresolved areas:
How will the federal policy affect patients enrolled in state medical marijuana programs?
Will marijuana grown by a registered patient or caregiver be treated as Schedule I or Schedule III?
Will the Department of Justice coordinate with the Centers for Medicare & Medicaid Services on coverage or reimbursement?
Could health insurance cover marijuana-based treatment received through a state medical marijuana program?
What will happen to businesses serving both medical and adult-use markets?
How will the Drug Enforcement Administration registration system work?
What patient and business information will the government collect, and how will it be protected?
How will federal enforcement apply to patients and businesses outside the new DEA registration framework?
The group requested answers from the administration by September 30, 2026.
These are questions—not promises. The administration’s answers could clarify future policy, but they do not guarantee that Medicare or private health insurers will begin paying for medical cannabis.
What Has Actually Been Rescheduled?
Federal marijuana policy in 2026 has two related tracks, and the distinction matters.
First, the Department of Justice established a Schedule III pathway for certain state-licensed medical marijuana products and FDA-approved marijuana products. The DEA subsequently opened a registration process for qualifying state-licensed medical cannabis businesses.
Second, the DEA held a separate administrative hearing from June 29 through July 15, 2026, on the broader proposal to transfer marijuana from Schedule I to Schedule III. Final briefs have been filed, but a final agency decision on that broader proceeding remains pending as of August 24, 2026.
The DEA’s official hearing notice explains that the broader proposal stems from the federal conclusion that marijuana has a currently accepted medical use and a lower abuse and dependence profile than Schedule I status reflects.
This does not amount to nationwide legalization. It also does not automatically place every dispensary, product or patient fully within the conventional federal prescription-drug system.
Congressional researchers have emphasized that the emerging framework may allow some state medical marijuana entities to comply with the Controlled Substances Act while leaving important questions under other federal laws unresolved. Recreational marijuana also remains federally prohibited.
Does Schedule III Automatically Mean Medicare Coverage?
No.
This is the biggest misconception surrounding the Medicare question.
Drug scheduling and insurance coverage are related, but they are not the same decision. Schedule III status can recognize accepted medical use under the Controlled Substances Act and can reduce certain barriers to research, registration and taxation. It does not require Medicare to reimburse every product within that schedule.
Medicare Part D generally covers qualifying prescription drugs that have received FDA approval and are included on a plan’s formulary. Coverage can also depend on the approved use, prior authorization, quantity limits, pharmacy network and other plan rules.
The CMS Medicare Part D manual defines a covered Part D drug as a prescription product approved by the FDA, subject to the program’s additional requirements.
Most medical marijuana sold through state-licensed dispensaries is not an FDA-approved prescription drug. A physician typically certifies or recommends a patient for a state program rather than writing a conventional prescription that can be filled at a federally regulated pharmacy.
That structure does not change simply because a cannabis product may fall under Schedule III.
For Medicare to broadly cover state-dispensary medical marijuana, federal agencies would likely need to resolve questions involving FDA approval, prescribing, product standardization, DEA registration, pharmacy dispensing, billing codes, reimbursement rules and Medicare’s statutory authority.
That is why the lawmakers’ request is important: it forces the administration to explain whether it sees a pathway from federal rescheduling to actual patient reimbursement.
Doesn’t Medicare Already Cover Some Cannabis-Based Medicines?
Medicare prescription plans may already cover certain FDA-approved cannabinoid medications when plan requirements are met—but that is different from covering medical marijuana purchased at a dispensary.
The FDA states that it has not approved cannabis itself to treat any disease or condition. It has approved one cannabis-derived medication, Epidiolex, and synthetic cannabis-related medicines including dronabinol and nabilone products.
These are standardized prescription drugs approved for specific medical uses. Their coverage depends on the patient’s plan and applicable coverage criteria.
Florida dispensary products—including flower, vapes, edibles, tinctures and many other preparations—are not automatically interchangeable with these FDA-approved
medications.
What About Medicare’s New Hemp Initiative?
CMS introduced a limited initiative in 2026 that allows certain participating healthcare organizations to furnish eligible hemp-derived products to qualifying Medicare beneficiaries under specified safeguards.
The Substance Access Beneficiary Engagement Incentive may allow approved participants in a small number of CMS Innovation Center models to provide up to $500 per year in eligible hemp products. The products must comply with strict limits, including federal hemp requirements, low THC thresholds and exclusions for inhaled products.
However, CMS explicitly says that this is not a Medicare coverage change. Medicare does not reimburse the participating provider for the products, and patients cannot submit dispensary or retail receipts to Medicare for payment.
The initiative is noteworthy because it introduces cannabinoid-related products into a carefully controlled federal healthcare model. It should not be confused with Medicare coverage of state-licensed medical marijuana.
What Could Medicare Coverage Look Like in the Future?
No federal agency has announced a final model, but several possibilities could emerge over time.
1. Coverage Limited to FDA-Approved Cannabis Medicines
This is the clearest path under the existing Medicare prescription-drug framework. More cannabis-derived products could undergo clinical trials, receive FDA approval and potentially be added to Medicare plan formularies.
2. A Demonstration or Pilot Program
CMS could test limited access through an Innovation Center model, much as it is currently doing with qualifying hemp products. Such a test would likely include strict eligibility, product, dosing, reporting and clinician-oversight requirements.
3. A New Federal Reimbursement Framework
Congress or federal agencies could attempt to create a specialized pathway for state-program medical marijuana. This would be far more complicated because current dispensary products, physician certifications and retail systems do not operate like standard Part D prescriptions.
4. No Broad Coverage Without Further Congressional Action
The administration could conclude that Medicare lacks the authority to reimburse state-dispensary cannabis under existing law. Congress would then have to consider legislation addressing coverage, product standards and payment.
Until federal officials respond, these remain possibilities—not established policy.
What Does This Mean for Medical Marijuana Patients?
For cannabis patients, nothing changes immediately.
The congressional letter does not:
Make Medicare pay for medical marijuana
Require private insurers to cover cannabis
Reimburse past dispensary purchases
Replace Florida’s medical marijuana certification process
Turn a physician certification into a standard federal prescription
Change Florida qualifying-condition requirements
Legalize recreational marijuana under federal law
Guarantee that every state-licensed cannabis product receives Schedule III protection
Eligible Florida patients must still be certified by a qualified physician, remain active in the Medical Marijuana Use Registry and purchase products through state-licensed medical marijuana treatment centers.
Patients should continue budgeting for certification, state fees and dispensary purchases as out-of-pocket expenses unless their insurer provides clear written notice of a specific covered benefit.
Do not rely on social-media posts or headlines suggesting that Medicare reimbursement has already begun.
Why the Medicare Question Still Matters
Although coverage has not changed, the conversation itself matters.
Medical marijuana patients are often older adults, veterans, people with disabilities and patients managing chronic or serious illnesses. These groups may already face substantial healthcare and prescription costs.
Paying separately for physician certification, state registration and medical cannabis can place treatment outside the reach of patients with limited incomes.
Insurance coverage could reduce that burden, but it would also bring new federal controls. Patients could encounter narrower product choices, required diagnoses, dose limits, prior authorization, approved pharmacies, standardized formulations and additional health-data reporting.
Coverage is therefore not only a question of who pays. It is also a question of which products qualify, who controls access and how patient privacy is protected.
Those are exactly the practical details Congress is now asking the administration to address.
OMNI’s Perspective: Clarity Must Come Before Headlines
The bipartisan letter is a meaningful development because it moves the Medicare question into a formal federal policy discussion.
A Republican lawmaker from Florida joined Democratic and Republican colleagues in asking how rescheduling will affect real patients—not only researchers and cannabis businesses.
Still, patients deserve careful language.
Schedule III does not equal Medicare coverage. A congressional question is not an approved benefit. A limited hemp initiative is not reimbursement for Florida dispensary products.
Federal reform may eventually make cannabis research easier, expand standardized treatment options and create new insurance pathways.
Until agencies publish enforceable rules, Florida’s medical marijuana program remains the practical legal framework for eligible patients in the state.
The Bottom Line
Bipartisan lawmakers have asked the Trump administration whether it plans to coordinate with CMS on Medicare coverage or reimbursement for Schedule III medical marijuana products. They have requested answers by September 30, 2026.
That request is an important step—but Medicare does not currently provide broad reimbursement for medical marijuana purchased from Florida dispensaries.
Patients should continue following Florida law, maintain an active medical marijuana certification and treat current cannabis expenses as out-of-pocket unless they receive verified coverage information directly from Medicare or their health plan.
OMNI Medical Services will continue monitoring federal guidance and explaining what new rules actually mean for Florida patients.
Apply or Renew With OMNI
Need to apply for or renew your Florida medical marijuana certification?
Medical & Legal Disclaimer
This article is provided for general educational and informational purposes only. It does not constitute medical advice, legal advice, insurance guidance or a guarantee of coverage.
Cannabis laws, federal scheduling rules, Medicare policies and Florida medical marijuana requirements may change. Always consult a qualified healthcare professional regarding treatment decisions, confirm coverage directly with Medicare or your insurance plan, and follow all applicable federal, state and local laws.
Cannabis products may cause side effects, impairment and drug interactions and may not be appropriate for every patient. Do not drive or operate machinery while impaired.
Comments